These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25430943)

  • 1. Anti-Nogo-A antibody: a treatment option for neurogenic lower urinary tract dysfunction?
    Schneider MP; Schwab ME; Kessler TM
    BJU Int; 2015 Apr; 115 Suppl 6():16-7. PubMed ID: 25430943
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-Nogo-A Antibodies As a Potential Causal Therapy for Lower Urinary Tract Dysfunction after Spinal Cord Injury.
    Schneider MP; Sartori AM; Ineichen BV; Moors S; Engmann AK; Hofer AS; Weinmann O; Kessler TM; Schwab ME
    J Neurosci; 2019 May; 39(21):4066-4076. PubMed ID: 30902870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nogo domains and a Nogo receptor: implications for axon regeneration.
    Brittis PA; Flanagan JG
    Neuron; 2001 Apr; 30(1):11-4. PubMed ID: 11343640
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunization with recombinant Nogo-66 receptor (NgR) promotes axonal regeneration and recovery of function after spinal cord injury in rats.
    Yu P; Huang L; Zou J; Yu Z; Wang Y; Wang X; Xu L; Liu X; Xu XM; Lu PH
    Neurobiol Dis; 2008 Dec; 32(3):535-42. PubMed ID: 18930141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerating corticospinal fibers in the Marmoset (Callitrix jacchus) after spinal cord lesion and treatment with the anti-Nogo-A antibody IN-1.
    Fouad K; Klusman I; Schwab ME
    Eur J Neurosci; 2004 Nov; 20(9):2479-82. PubMed ID: 15525289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nogo A protein neutralisation and motor cortex computer implants: a future hope for spinal cord injury.
    Alisky JM
    Singapore Med J; 2007 Jun; 48(6):596-7. PubMed ID: 17538769
    [No Abstract]   [Full Text] [Related]  

  • 7. Nogo-66 receptor antagonist peptide promotes axonal regeneration.
    GrandPré T; Li S; Strittmatter SM
    Nature; 2002 May; 417(6888):547-51. PubMed ID: 12037567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats.
    Liebscher T; Schnell L; Schnell D; Scholl J; Schneider R; Gullo M; Fouad K; Mir A; Rausch M; Kindler D; Hamers FP; Schwab ME
    Ann Neurol; 2005 Nov; 58(5):706-19. PubMed ID: 16173073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Nogo on the go: from animal models to a clinical trial.
    Zörner B; Schwab ME
    Ann N Y Acad Sci; 2010 Jun; 1198 Suppl 1():E22-34. PubMed ID: 20590535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness.
    Gonzenbach RR; Zoerner B; Schnell L; Weinmann O; Mir AK; Schwab ME
    J Neurotrauma; 2012 Feb; 29(3):567-78. PubMed ID: 21815784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A.
    Weinmann O; Schnell L; Ghosh A; Montani L; Wiessner C; Wannier T; Rouiller E; Mir A; Schwab ME
    Mol Cell Neurosci; 2006; 32(1-2):161-73. PubMed ID: 16697217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of Jisuikang on Nogo-NgR gene expression in spinal cord rats with injury].
    You WL; Zhang YF; Chen JF; Yin H; Yang JF; Wang JW
    Zhongguo Gu Shang; 2015 Mar; 28(3):235-9. PubMed ID: 25936193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury: long-term urodynamic findings.
    Schöps TF; Schneider MP; Steffen F; Ineichen BV; Mehnert U; Kessler TM
    BJU Int; 2015 Apr; 115 Suppl 6():33-8. PubMed ID: 25891318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Nogo and Nogo receptor during the development of the entorhino-hippocampal pathway and after adult hippocampal lesions.
    Mingorance A; Fontana X; Solé M; Burgaya F; Ureña JM; Teng FY; Tang BL; Hunt D; Anderson PN; Bethea JR; Schwab ME; Soriano E; del Río JA
    Mol Cell Neurosci; 2004 May; 26(1):34-49. PubMed ID: 15121177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nogo-66 receptor: focusing myelin inhibition of axon regeneration.
    McGee AW; Strittmatter SM
    Trends Neurosci; 2003 Apr; 26(4):193-8. PubMed ID: 12689770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charcot arthropathy of the spine in spinal cord injured individuals with sacral deafferentation and anterior root stimulator implantation.
    Krebs J; Grasmücke D; Pötzel T; Pannek J
    Neurourol Urodyn; 2016 Feb; 35(2):241-5. PubMed ID: 25524388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury.
    Kim JE; Liu BP; Park JH; Strittmatter SM
    Neuron; 2004 Oct; 44(3):439-51. PubMed ID: 15504325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling.
    Mingorance A; Solé M; Munetón V; Martínez A; Nieto-Sampedro M; Soriano E; del Río JA
    FASEB J; 2006 Mar; 20(3):491-3. PubMed ID: 16407455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why do Nogo/Nogo-66 receptor gene knockouts result in inferior regeneration compared to treatment with neutralizing agents?
    Teng FY; Tang BL
    J Neurochem; 2005 Aug; 94(4):865-74. PubMed ID: 16092935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide reverses spinal cord damage.
    Schub T
    Lab Anim (NY); 2002; 31(7):13. PubMed ID: 14619844
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.